Cargando…
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
Autores principales: | Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478640/ https://www.ncbi.nlm.nih.gov/pubmed/34373585 http://dx.doi.org/10.1038/s41375-021-01373-4 |
Ejemplares similares
-
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014) -
De-Novo Design
of Cereblon (CRBN) Effectors Guided
by Natural Hydrolysis Products of Thalidomide Derivatives
por: Heim, Christopher, et al.
Publicado: (2019) -
PB1958: IN SILICO ANALYSIS OF SYNONYMOUS AND NON-SYNONYMOUS SNPS OF THE HUMAN CEREBLON (CRBN) GENE: AN IMPORTANT GENE IN IMMUNOMODULATORY DRUGS (IMIDS)-BASED TREATMENT OF MULTIPLE MYELOMA PATIENTS
por: Güler, M., et al.
Publicado: (2022) -
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012) -
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)